MARKET

HGEN

HGEN

Humanigen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.73
-0.83
-5.33%
After Hours: 14.76 +0.03 +0.20% 19:29 04/16 EDT
OPEN
15.55
PREV CLOSE
15.56
HIGH
15.55
LOW
14.66
VOLUME
997.01K
TURNOVER
--
52 WEEK HIGH
33.95
52 WEEK LOW
3.870
MARKET CAP
787.80M
P/E (TTM)
-6.6283
1D
5D
1M
3M
1Y
5Y
Prosecutor: Shkreli may be slapped with new charges
Martin Shkreli made an appearance at the U.S. Federal Court in Brooklyn on Tuesday for a hearing related to securities fraud charges.
CNBC.com · 2d ago
Global Chagas Disease Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Chagas Disease Drug market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 3d ago
Cramer Weighs In On Paysafe, Xilinx And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Keysight Technologies Inc (NYSE: KEYS) has been just red hot and he really likes it.
Benzinga · 3d ago
Cramer's lightning round: I want to buy Paysafe
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 4d ago
DJ Humanigen Price Target Raised to $36.00/Share From $34.00 by HC Wainwright & Co.
Dow Jones · 6d ago
Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?
Zacks.com · 04/09 22:31
Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study
Benzinga · 04/09 12:28
DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
Dow Jones · 04/09 11:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HGEN. Analyze the recent business situations of Humanigen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HGEN stock price target is 34.33 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 13.92M
% Owned: 26.02%
Shares Outstanding: 53.48M
TypeInstitutionsShares
Increased
6
228.71K
New
23
2.88M
Decreased
4
796.34K
Sold Out
11
3.97M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Chief Executive Officer/Director
Cameron Durrant
Chief Financial Officer/Chief Operating Officer/Chief Accounting Officer/Chief Administrative Officer
Timothy Morris
Senior Vice President
Omar Ahmed
Chief Scientific Officer/Director
Dale Chappell
Other
Edward Jordan
Independent Director
Ronald Barliant
Independent Director
Rainer Boehm
Independent Director
Cheryl Buxton
No Data
About HGEN
Humanigen, Inc., formerly KaloBios Pharmaceuticals, Inc., is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company's product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. It is engaged in developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia both of which are rare hematologic cancers. It is exploring development of another of its monoclonal antibodies, ifabotuzumab, for the treatment of rare solid and hematologic cancers. Its KB001-A, is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), and infections in mechanically ventilated patients and cystic fibrosis (CF).

Webull offers kinds of Humanigen Inc stock information, including NASDAQ:HGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HGEN stock methods without spending real money on the virtual paper trading platform.